uniQure NV
Open
42.3 5.51
Overzicht
Wijziging aandelenprijs
24u
Min
39.59
Max
42.36
Inkomsten | -16M -54M |
|---|---|
Verkoop | -2M 3.6M |
EPS | -0.73 |
Winstmarge | -1,502.948 |
Werknemers | 221 |
EBITDA | 13M -36M |
Aanbevelingen | Strong Buy |
|---|---|
12 Maanden Prognose | +63.96% upside |
Marktkapitalisatie | 1.3B 2.6B |
|---|---|
Vorige openingsprijs | 36.79 |
Vorige sluitingsprijs | 42.3 |
uniQure NV Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
uniQure NV Prognose
Koersdoel
By TipRanks
63.96% opwaarts potentieel
12 Maanden Prognose
Gemiddelde 65.7 USD 63.96%
Hoogste 95 USD
Laagste 37 USD
Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor uniQure NV - Dist. in de afgelopen 3 maanden.
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over uniQure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.